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Abstract
Background: Hypoxia-inducible factor 1 (HIF-1) is a master transcriptional regulator of genes regulating oxygen
homeostasis. The HIF-1 protein is composed of two HIF-1a and HIF-1b/aryl hydrocarbon receptor nuclear
translocator (ARNT) subunits. The prognostic relevance of HIF-1a protein overexpression has been shown in breast
cancer. The impact of HIF-1a alternative splice variant expression on breast cancer prognosis in terms of metastasis
risk is not well known.
Methods: Using real-time quantitative reverse transcription PCR assays, we measured mRNA concentrations of total
HIF-1a and 4 variants in breast tissue specimens in a series of 29 normal tissues or benign lesions (normal/benign)
and 53 primary carcinomas. In breast cancers HIF-1a splice variant levels were compared to clinicopathological
parameters including tumour microvessel density and metastasis-free survival.
Results: HIF-1a isoforms containing a three base pairs TAG insertion between exon 1 and exon 2 (designated
HIF-1a
TAG) and HIF-1a
736 mRNAs were found expressed at higher levels in oestrogen receptor (OR)-negative
carcinomas compared to normal/benign tissues (P = 0.009 and P = 0.004 respectively). In breast carcinoma
specimens, lymph node status was significantly associated with HIF-1a
TAG mRNA levels (P = 0.037). Significant
statistical association was found between tumour grade and HIF-1a
TAG (P = 0.048), and total HIF-1a (P = 0.048)
mRNA levels. HIF-1a
TAG mRNA levels were also inversely correlated with both oestrogen and progesterone receptor
status (P = 0.005 and P = 0.033 respectively). Univariate analysis showed that high HIF-1a
TAG mRNA levels
correlated with shortened metastasis free survival (P = 0.01).
Conclusions: Our results show for the first time that mRNA expression of a HIF-1a
TAG splice variant reflects a stage
of breast cancer progression and is associated with a worse prognosis.
See commentary: http://www.biomedcentral.com/1741-7015/8/45
Background
Hypoxia-inducible factor 1 (HIF-1) is a ubiquitously
expressed master transcriptional regulator of many
genes regulating mammalian oxygen homeostasis [1,2].
HIF-1 alters transcription of genes mainly involved in
energy metabolism, neovascularisation, survival, internal
pH and cell migration, and has become recognised as a
strong promoter of tumour growth [3,4]. HIF-1 is a
heterodimeric protein composed of two HIF-1a and
HIF-1b/aryl hydrocarbon receptor nuclear translocator
(ARNT) subunits [5]. These subunits are members of
the basic helix-loop-helix (bHLH) transcription factor
superfamily containing a PAS [PER (Period Clock)
-ARNT-SIM (Single-minded)] domain [2]. The HIF-1a
subunit is specific to HIF-1 and is the unique oxygen-
regulated subunit that determines HIF-1 activity [6,7]
whereas HIF-1b is a common subunit for several tran-
scription factors. In human tumours, HIF-1a protein is
overexpressed because of intratumoural hypoxia and
genetic alterations affecting key oncogenes and tumour
suppressor genes [8,9]. This overexpression correlates
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mortality [3].
Our group and others have previously reported that
HIF-1a protein overexpression is a marker of poor
prognosis in primary breast cancer patients [10,11].
HIF-1a i sk n o w nt ob em a i n l yp o s t - t r a n s c r i p t i o n a l l y
regulated by protein ubiquitination and interaction with
the Von Hippel-Lindau tumour suppressor protein, and
then degraded by the proteasome. Hypoxia stabilises
HIF-1a protein by relaxing its ubiquitin-proteasome
degradation [12] and affects subcellular localisation,
DNA binding capacity and transcriptional activation
function of the HIF-1 complex. HIF-1a protein is
composed of 826 amino acids [5]. Its N-terminal region
contains the bHLH and the PAS domains, which are
essential for DNA binding and dimerisation [13]. Its
C-terminal region contains two transactivation domains
and a nuclear localisation signal [14]. In the middle sec-
tion of HIF-1a lies a Pro-Ser-Thr oxygen-dependent
degradation domain (ODDD, amino acids 401 to 603),
which is responsible for the stability of the HIF-1a pro-
tein [12].
Although HIF-1a protein regulation has been well
studied, HIF-1a messenger regulation has only recently
begun to be documented [15]. HIF-1a is encoded by the
HIF1A locus, which is located on human chromosome
14q21-q24 and encodes for 15 exons, resulting in a
principal transcript of about 8 kb [16]. Different func-
tional domains of the HIF-1a protein are encoded by
separate exons. In addition to the originally described
wild type of HIF-1a (HIF-1a
WT) [1], eight alternative
splice variants of HIF-1a (HIF-1a
827,H I F - 1 a
736,
HIF-1a
557,H I F - 1 a
516,H I F - 1 a
785,H I F - 1 a
417,H I F - 1 a
TE
and an isoform with alternative exon 1 (I.2 isoform))
with different activity have been reported in human cell
lines [17-23]. All HIF-1a splice variants have been
shown to be translated, to dimerise with HIF-1b and to
be active in human cells. Only one isoform (HIF-1a
736)
has been documented in human breast cancer [24]. The
a i mo ft h i ss t u d yw a st oa n a l y s eHIF-1a splice variant
expression in human breast cancer and to evaluate its
clinical relevance in terms of prognosis. In this study we
quantified the mRNA levels of 3 isoforms (HIF-1a
736,
HIF-1a
557 and HIF-1a
516) in breast specimens of 53
primary cancers and 29 normal tissues or benign lesions
by real-time quantitative reverse transcription PCR
(RT-qPCR) assays. HIF-1a
827 is similar to wild type
except for an additional three base pairs TAG insertion
at the exon 1 to 2 junction involving a difference of two
amino acids upstream of the bHLH domain [17].
HIF-1a
736 is also characterised by an additional three
base pairs TAG insertion at the exon 1 to 2 junction,
and the lack of exon 14, which produces a frame shift
and introduces a stop codon in the coding sequence
after the Ile
735 [17]. HIF-1a
557 loses exon 12 and
HIF-1a
516 lacks exons 11 and 12 [18,19]. HIF-1a
557 has
been shown to be induced by zinc ions. HIF-1a
557 and
HIF-1a
516 have been shown to function as dominant
negative isoforms of HIF-1a in vitro. HIF-1a
785 is
deprived of exon 11 and was described as being induced
in vitro by phorbol-12-myristate-13-acetate [20].
HIF-1a
417 isoform is deprived of exon 10 [21]. The
HIF-1a
TE variant with alternative exon 1 (I.1 isoform)
was previously found to be expressed in the testis [22].
For these reasons, both these isoforms were thought to
be out of the scope of this study on breast tissues sam-
ples. We also developed tools to quantify expression of
HIF-1a splice transcripts characterised by insertion of a
three base pairs TAG at the exon 1 to 2 junction (which
we designated HIF-1a
TAG) involving a difference of two
amino acids upstream of the bHLH domain (HIF-1a
827
and HIF-1a
736 isoforms) [17]. The last known isoform
was not quantified because it was described in humans
after the end of our study [23]. Expression levels of
these isoforms were also compared to standard prognos-
tic clinicopathological parameters, microvessel density of
tumours and clinical outcome.
Methods
Patients and breast tissue samples
A series of 29 normal tissues or benign lesions (normal/
benign) of breast tissue and 53 primary invasive breast
carcinomas tissue specimens were selected. All frozen
tissues were available in the tumour library of the
Department of Pathology (Hôpital Nord, Assitance Publi-
que-Hôpitaux de Marseille, France). Each patient gave
informed consent and the study was approved by our
institutional review board. Within 15 min of excision
fresh tissue samples were frozen in liquid nitrogen by the
pathologist (freezing delay shorter than 15 min). All tis-
sue specimens were then stored at -80°C and were never
thawed (freezers under temperature control 24 h a day).
Specimens of normal breast tissues were obtained from
adjacent tumour-free tissue taken from 12 breast cancer
patients. Benign lesions were obtained from women
undergoing surgery for fibroadenoma (n = 13) or adeno-
sis (n = 4). Normal/benign tissues were obtained from 29
patients aged from 12 to 79 years (mean 44.7 years, SD
16.9). Malignant tumour specimens represented 53 early
invasive breast adenocarcinomas diagnosed between
9 September 1989 and 1 May 1996. Tumour tissue speci-
m e n sw e r eo b t a i n e df r o mp a t i e n t sa g e df r o m3 0t o
84 years (mean 54 years, SD 11.4). Surgery was in all
cases the first treatment. The patients underwent axillary
node excision combined with wide local excision with
margin clearance or mastectomy according to current
European recommendations in the department of Onco-
logic Gynaecology in Hôpital de la Conception, Marseille.
Dales et al. BMC Medicine 2010, 8:44
http://www.biomedcentral.com/1741-7015/8/44
Page 2 of 11For this first step of treatment, patient management was
h a n d l e db yt h es a m eg r o u po f surgeons (PB). Likewise,
radiotherapy, chemotherapy and hormone therapy were
applied according to criteria currently used at that time.
Each of the respective areas was identified microscopi-
cally and dissected immediately upon receipt of the
breast specimen by the pathologist. The tumour content
of each specimen was verified by histological examination
of frozen section by haematoxylin staining. Histological
examination of surgical specimens was also performed
on paraffin embedded sections stained with haematoxy-
lin, eosin and saffronin. Tumour grading, initially
assessed by using the grading methods of Bloom
and Richardson [25], was re-evaluated according to
Elston and Ellis [26]. Duration of follow-up ranged from
9 to 162 months (mean 80 months, SD 43). For statistical
purposes, we selected approximately equal numbers of
long (n = 31) and short metastasis-free survival patients
(n = 22).
Clinical and pathological parameters
Lymph node status, tumour size, peritumoural vascular
invasion, histological type and histological grade of
tumours were obtained from pathological reports. The
oestrogen receptor (OR) and progesterone receptor
(PgR) status was determined by immunohistochemistry
on paraffin-embedded sections as previously described
[27,28].
Tumour microvascular density
Immunodetection studies were performed on frozen
sections 5 ?m thick and automated immunoperoxidase
procedures as previously reported [29].
RNA extraction and reverse transcription
Homogenising Trizol procedures have been performed in
accordance with current protocols. Frozen tissue (25 to 50
mg) was homogenised in 0.5 ml Trizol reagent (Life Tech-
nologies, Carlsbad, California) with lysing matrix D in a
FastPrep machine (Q-BIOgene, MP Biomedicals, Illkirch,
France) for six cycles of 30 s at a setting of 6 m/s as
recommended by the manufacturer. Chloroform (100 μl)
was added to each sample, which were mixed vigorously
for 15 s and incubated for 3 min at room temperature.
Phases were separated by centrifugation (12,000 g for
15 min at 4°C) and the aqueous phase was recovered. Iso-
propanol (250 μl) was added to each of the samples, which
were then mixed by inversion and incubated for 10 min at
room temperature. Total RNA was pelleted by centrifuga-
tion (12,000 g for 10 min at 4°C), washed with 1 ml of ice-
cold 75% ethanol, air dried and resuspended in 15 μl
Rnase-free distilled water. Then, 1 μg of RNA was reverse
transcribed with 200 U MMLV Reverse Transcriptase
following the Europe Against Cancer (EAC) protocol [30].
Generation of standard plasmids
pcDNA3 plasmids containing HIF-1a
827 and HIF-1a
736
sequences with the three base pairs TAG insertion were
kindly provided by J Pouyssegur (Institut de Signalisation,
Biologie du Développement et Cancer, Centre Lacassagne,
Nice, France). For other splice variants, cDNA from
human embryonic kidney (HEK)293 cells was amplified
using the following primers, respectively localised in exons
1 and 2: forward, 5′-CCGGCGGCGCGAACGACAAG-3′,
reverse, 5′-TGCGAACTCACATTATGTGG-3′,o rp r i -
mers localised in exons 10 and 14, respectively: forward,
5′-TGACCCTGCACTCAATCAAG-3′, reverse, 5′-AGTA-
GCTGCATGTACGTCTG-3′. Conditions for PCR ampli-
fication were: 10 min denaturation at 95°C followed by 35
cycles of 30 s at 95°C, 1 min at 55°C, 1 min at 72°C, and
the last elongation at 72°C for 10 min. If necessary, DNA
bands of interest were isolated and purified from 2% agar-
ose gel and cloned into the pCRII TOPO vector (TOPO-
TA cloning kit, Invitrogen, Life Technologies, Carlsbad,
California) according to the manufacturers. Plasmids were
purified (Nucleospin plasmid, Macherey Nagel, Hoerdt,
France) and the cloned inserts were sequenced. Serial
dilutions were prepared in Escherichia coli rRNA (Roche
Diagnostics, Meylan, France) to generate RT-qPCR stan-
dard curves (PCT international application no. 02/00937
o f1 5M a r c h2 0 0 2 ,i nt h en a m eo fU n i v e r s i t éd el aM é d i -
terranée) according to the EAC strategy [30].
Design
mRNA sequences of four spliced variants (HIF-1a
TAG,
HIF-1a
736, HIF-1a
557 and HIF-1a
516)w e r ec o n s t r u c t -
ed using the human HIF-1a transcript sequence
NM_001530 as a reference. Primer and probe sets were
designed using the Primer Express software (Applied
Biosystems, Courtaboeuf, France) and chosen based on
their exon-exon junction location (Figure 1). HIF-1a
736,
HIF-1a
557 and HIF-1a
516 splice variant specific TaqMan
assays, and an assay specific to a common region pre-
sent in all known variants and located at exons 5 and 6,
were designed. Specific probes and primers on adjacent
exons were also designed to detect HIF-1a transcripts
containing a three base pairs TAG insertion between
exon 1 and exon 2 (which we designated HIF-1a
TAG).
For this variant, primers and probes were designed to
detect intron length between exons rather than
exon-exon junctions. The length of introns between
these exons on DNA is long enough to avoid DNA
amplification.
Optimisation of RT-qPCR
Amplification and quantification of HIF-1a variants was
performed on a MX3000P system (Stratagene, Agilent
Technologies, Santa Clara, California). Amplifications
were performed on specific plasmid serial dilutions of
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TaqMan universal PCR MasterMix (Applied Biosys-
tems, Courtaboeuf, France) and both forward and
reverse primers and probes. Different ranges of primer
concentrations were tested and optimised for each
amplicon to obtain the most specific, sensitive and effi-
cient RT-PCR amplification. Selected primer and probe
concentrations are shown in Table 1. Optimised
RT-qPCR reaction conditions for gene amplification
were as follows: 50°C for 2 min, denaturation for
1 0m i na t9 5 ° Cf o l l o w e db y5 0c y c l e so f3 0sa t9 5 ° C ,
1 min annealing and extension at 60°C for all tran-
scripts except for HIF-1a
TAG with 1 min at 62°C. For
validation of assays specificity, the primers and probes
used to detect each splice variant were tested by RT-
PCR with 1 μg RNA of the HEK293 cell line (DSMZ),
1 μg genomic DNA of peripheral blood mononuclear
cells (PBMCs) and standards (10
6 copies of plasmids)
specific for another splice variant. No template control
(NTC) was also performed. RT-qPCR products were
analysed by Agilent 2100 Electrophoresis Bioanalyzer
(Agilent Technologies, Santa Clara, California). Serial
dilutions of specific standard plasmids were used to
validate sensitivity, linearity and detection limits of
RT-qPCR assays. Intrareproducibility and inter-reprodu-
cibility assays were performed by four RT-qPCR experi-
ments, each time in triplicate.
RT-qPCR assays
Amplifications were performed with 5 μlo fc D N Ao f
each sample using RT-qPCR optimised conditions as
previously described. mRNA from HEK293 cells was
used as positive control throughout the study. Standard
(10
6 copies of plasmid) specifics of another splice variant
were amplified as negative control throughout the study
and NTC was performed. Standard curves were gener-
ated by serial dilutions of HIF-1a splice variant plasmids
ranging from 1 to 10
6 copies and used for calculation of
copy numbers (CN) for each transcript. Transcripts of
the gene coding for the TATA box-binding protein
(TPB) were also quantified as endogenous gene controls,
and each sample was normalised on the basis of its TBP
content as previously described [31]. All experiments
were carried out with duplicates for each data point. For
each experiment sample, the mRNA copy number of
HIF-1a gene (CNHIF-1a) and endogenous reference TBP
gene (CNTBP)w e r eq u a n t i f i e df r o ms t a n d a r dc u r v e s .
Final HIF-1a mRNA concentrations were expressed in
Figure 1 Position of primers and oligonucleotide probes designed to amplify hypoxia inducible factor 1a (HIF-1a)m R N As p l i c e
variants. The diagram illustrates the combination of primers and probes used to detect mRNA of four alternative spliced isoforms of HIF-1a.
Boxes represent exons designated by 1 to 15. Primers are indicated by solid arrowhead and probe by thick solid lines. Wild-type HIF-1a (HIF-
1a
wt) mRNA consists of 15 exons and 14 introns. Variants reported here are generated by a TAG insertion between exon 1 and exon 2 (HIF-1a
827
and HIF-1a
736), exon 13 to 15 alternative splicing (HIF-1a
736), exon 11 to 13 alternative splicing (HIF-1a
557) and exon 10 to 13 alternative splicing
(HIF-1a
516). Primers on exons 5 and 6 (asterisk) are suitable for quantification of all HIF-1a transcripts including HIF-1a
wt as well as each isoform.
Primers pairs on exons 13 and 15, 11 and 13, 10 and 13 are suitable for specific detection of HIF-1a
736, HIF-1a
557 and HIF-1a
516 variants
respectively. Note that primers on exons 1 and 2 allow mRNA detection of both isoforms HIF-1a
827 and HIF-1a
736.
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NCNHIF-1a = CNHIF-1a/CNTBP.
Statistical analysis
Differences among groups of breast tissue specimens
(normal/benign tissues vs carcinomas) in terms of their
HIF-1a mRNA levels were assessed using Kruskal-Wallis
and Mann-Whitney tests with Bonferroni correction.
Since levels of expression in breast cancer specimens
showed non-Gaussian distribution, non-parametric tests
were used for the analysis of correlation with clinico-
pathological parameters. Metastasis-free survival (MFS)
time, defined as the time from surgery until diagnosis of
metastasis, was used as a follow-up endpoint. Regression
models (univariate and multivariate) were used to com-
pare survival and identify predictors of survival. All pre-
operative predictors (clinicopathological and biological
parameters) were included in the analysis. The predic-
tors with P v a l u e<0 . 2 0i nt h eu n i v a r i a t em o d e lw e r e
tested in the multivariate regression model. Then back-
ward conditional method was used for variable selection
by the Cox multivariate regression model. Finally, vari-
ables with adjusted P values < 0.05 were kept into the
final model. All statistical analyses were performed with
SPSS V.13.0.1 software (SPSS, Chicago, IL, USA).
Results
Clinicopathological parameters
Tumour characteristics are summarised in Table 2.
Tumours corresponded to ductal carcinomas (n = 41)
and lobular carcinomas (n = 12). Tumours were grade 1
i n9c a s e s ,g r a d e2i n2 6c a s e sa n dg r a d e3i n1 7c a s e s .
A mean of 16.9 (SD ± 5.1) lymph nodes were found in
axillary node excision, and 22 patients were node posi-
tive. All patients underwent axillary node excision com-
bined with wide local excision with margins clearance
or mastectomy in the same department. Treatment post
surgery consisted of radiotherapy, chemotherapy and
hormone therapy performed by the same group of
oncologists. Duration of follow-up ranged from 9 to
162 months. The 2004 records showed that among
53 patients, 22 (41.5%) patients relapsed, among whom
18 died.
Optimisation and validation of RT-PCR assays
Primers and probes sets for HIF-1a variants were tested
using RT-qPCR on the HEK293 RNA and specific stan-
dard plasmids. Primer concentration optimisation assays
were carried out to determine the optimal concentra-
tions for each primer and probe set. To test the specifi-
city and crossreaction of the primers used for RT-qPCR,
experiments were performed using genomic DNA, stan-
dard plasmids specific of another splice variant, and
n N T C .N oa m p l i f i c a t i o nw a so b s e r v e dw i t hg e n o m i c
DNA of PBMCs, specific standard plasmids of other
splice variants and NTC. Serial dilutions of HIF-1a var-
iants specific standard plasmid were used to generate a
standard curve to assess the intra-assay and interassay
reproducibility and sensitivity. For each variant, excel-
lent reproducibility and linearity of standard curves
Table 1 Details of oligonucleotide sequences of primers and probes used to quantify hypoxia inducible factor 1a
(HIF-1a) mRNA splice variants by real-time quantitative reverse transcription PCR assays
Oligonucleotide Position (exon) 5’ Position Sequence (5’ to 3’) Primer/probe
concentrations (nM)
Amplicon size
5 518 F: GTACCCTAACTAGCCGAGGAAGAA 300
6 597 R: GTGAATGTGGCCTGTGCAGT 300
HIF-1a (total) 5 to 6 junction 544 P: ATGAACATAAAGTCTGCAACATGGAAGGTATTG 200 80 bp
1 17 F: GCGCGAACGACAAGAAAAATAG 50
2 138 R: TGGCAACTGATGAGCAAGCT 300
HIF-1a
TAG 2 74 P: ATGCAGCCAGATCTCGGCGAAGTAAA 200 122 bp
13 to 15 junction 2,182 F: TCACTTTTTCAAGCAGTAGGAATTATTTAG 600
15 2,330 R: TAATTCTTCACCCTGCAGTAGGTTT 600
HIF-1a
736 15 2,260 P: TGACCAGTTATGATTGTGAAGTTAATGCTCCTATACAAGG 200 149 bp
11 1,566 F: TGTGGATAGTGATATGGTCAATGAATT 300
13 1,699 R: TAGTATCTTTGGATTTAGTTCTTCCTCAGG 300
HIF-1a
557 11 to 13 junction 1,642 P: AAGCAAACCCATTTTCTACTCAGAACTACA 200 134 bp
10 1,490 F: AGACACCTAGTCCTTCCGATGG 600
13 1,580 R: AAGCTAGTATCTTTGGATTTAGTTCTTCCT 600
HIF-1a
516 10 to 13 junction 1,513 P: AGCACTAGACAAAGTTCACCTGAGAACTACAGT 200 91 bp
The mRNA sequences of four alternatively spliced variants (HIF-1a
TAG, HIF-1a
736, HIF-1a
557 and HIF-1a
516) were constructed using the human HIF-1a transcript
sequence NM_001530. bp = base pairs; F = forward primer; P = oligonucleotide probe; R = reverse primer.
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between -3.31 and -3.55, which correspond to efficien-
cies higher than 92% and coefficients of correlation
between 0.993 and 1. The assays sensitivity was found at
10 copies for all variants. We did not succeed in quanti-
fying the HIF-1a
417 isoform.
Differential expression of HIF-1a splice variants in
normal/benign and malignant breast tissues
Expression levels of HIF-1a mRNAs were determined in
each of the 82 samples of breast tissue. HIF-1a splice
variants were detected in every sample of normal/benign
and malignant breast tissues at varying levels.
HIF-1a
TAG mRNA levels were higher than the other
HIF-1a splice variants in the majority of breast tissues,
and low levels were only found for HIF-1a
736, HIF-1a
516
and HIF-1a
557 isoforms (Figure 2). HIF-1a
TAG mRNAs
were expressed at similar levels to the total HIF-1a
expression suggesting that unknown isoforms devoid of
exons 5 and 6 may contain the three base pairs TAG
insertion. Splice variants HIF-1a
736 and HIF-1a
516
mRNAs were expressed 100-fold lower than HIF-1a
TAG
and variant HIF-1a
557 mRNA was expressed at levels
1,000-fold lower than HIF-1a
TAG. Expression levels of
HIF-1a
516 and HIF-1a
557 mRNA that were very low
(mean normalised copy numbers < 0.1) were not
included in statistical analyses. There was no significant
statistical difference in the total HIF-1a expression
between normal/benign and malignant breast tissues.
HIF-1a
TAG mRNAs were also expressed at similar level
between the two categories of tissues. HIF-1a
736
mRNAs showed a link with malignant phenotype but
did not reach statistical significance (P = 0.053). Inter-
estingly, HIF-1a
TAG and HIF-1a
736 mRNAs were found
to be expressed at higher levels in OR-negative carcino-
mas compared to normal/benign tissues (P = 0.009 and
P = 0.004 respectively) (Figure 3). HIF-1a
TAG mRNAs
were also higher in OR-negative carcinomas compared
to OR-positive ones (P = 0.005).
HIF-1a splice variants expression correlates with
prognostic clinicopathological parameters of breast
cancer
Levels of each HIF-1a variant mRNA were determined
in tumour samples from 53 patients with breast cancer
and were compared with lymph node status, tumour
size, tumour grade, peritumoural vascular invasion, OR
and PgR status. They were also compared with micro-
vessel density of tumours (Table 3). Lymph node status
was significantly associated with HIF-1a
TAG mRNA
levels (P = 0.037). Statistically significant association was
found between tumour grade and total HIF-1a (P =0 . 0 4 8 )
or HIF-1a
TAG (P = 0.048). Peritumoural vascular invasion
correlated with total HIF-1a (P = 0.028). Interestingly
HIF-1a
TAG mRNA levels inversely correlated with both
OR and PgR status. No significant association was found
between any of the HIF-1a mRNA levels and tumour size
or microvessel density.
Expression of HIF-1a
TAG splice variant correlates with
patient survival
The strength of association between clinicopathological
tumour characteristics (lymph node status, tumour size,
tumour grade, peritumoural invasion, OR and PgR sta-
tus, tumour microvessel density) and expression levels
of HIF-1a mRNAs with metastasis-free survival is
shown in Table 4. Lymph node status (P = 0.003), OR
status (P = 0.021), PgR status (P =0 . 0 0 5 )a n dHIF-
1a
TAG mRNA levels (P = 0.01) were found to be signifi-
cantly predictive of metastasis free survival. HIF-1a
TAG
mRNAs were expressed at varying levels. In our series,
we used the median value (9.95) of these levels as a cut
Table 2 Distribution of clinical and histopathological
characteristics of breast cancer patients
Parameter No. of patients No. of patients
with metastasis
Age, years:
≤ 50 21 8
>5 0 3 0 1 3
Positive lymph node:
02 5 6
1 to 3 11 9
4t o1 0 4 3
>1 0 7 3
Pathological tumour size, mm:
≤ 10 3 1
11 to 20 25 8
21 to 50 23 12
>5 0 2 1
Tumour grade:
19 1
22 6 1 3
31 7 8
Histological type:
Tubular 41 18
Lobular 12 4
Peritumoural vascular invasion:
Absent 12 4
Present 40 18
OR status:
OR positive 32 10
OR negative 16 10
PgR status:
PgR positive 26 6
PgR negative 24 16
Because of missing data, the numbers do not always add up to 53.
OR = oestrogen receptor; PgR = progesterone receptor.
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mRNA levels higher than 9.95 was considered as a high
level of expression and the group with mRNA levels
lower than 9.95 was considered as a low level of expres-
sion) to evaluate their association with metastasis survi-
val. Breast cancer patients with high expression levels of
HIF-1a
TAG mRNA had a significantly higher risk of
relapse (Figure 4). Expression levels of the other HIF-1a
transcripts were not associated with prognosis (not
shown). Multivariate Cox analysis identified lymph node
status (P = 0.005) and PgR status (P = 0.012) as inde-
pendent predictors of metastasis free survival. HIF-
1a
TAG mRNA levels did not remain a significant
independent prognostic variable.
Figure 2 Distribution of hypoxia inducible factor 1a (HIF-1a) mRNA levels in 82 breast tissues determined by real-time quantitative
reverse transcription PCR assay. HIF-1a mRNA levels were expressed in normalised copy numbers (NCN) on the basis of TATA box-binding
protein (TPB) gene content of the tissues as described in the Methods section. Patients grouped according to histological type of tissues (x axis).
HIF-1a mRNA levels (y axis) were represented according to these different groups of patients. Results were plotted on a logarithmic scale. HIF-1a
splice variants were detectable in all samples at varying levels. Splice variant HIF-1a
736 and HIF-1a
516 mRNAs were expressed at levels 100-fold
lower than HIF-1a
TAG. Variant HIF-1a
557 mRNAs that were expressed at levels 1,000-fold lower than HIF-1a
TAG are not shown.
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Figure 3 Distribution of hypoxia inducible factor 1a (HIF-1a)
TAG and HIF-1a
736 mRNA levels in 82 breast tissues determined by real-
time quantitative reverse transcription PCR assay. HIF-1a mRNA levels were expressed in normalised copy numbers (NCN) on the basis of
TATA box-binding protein (TPB) gene content of the tissues as described in the Methods section. Patients grouped according to histological
type of tissues (x axis). HIF-1a
TAG and HIF-1a
736 mRNAs were expressed at higher levels in oestrogen receptor (OR)-negative carcinomas
compared to normal/benign tissues (P = 0.009 and P = 0.004 respectively). HIF-1a
TAG mRNAs were also higher in OR-negative carcinomas
compared to OR-positive ones (P = 0.005).
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Several isoforms of HIF-1a resulting from alternative
splicing have been described in various human tumour
cell lines or tissues. Only one isoform (HIF-1a
736)h a s
been documented in human breast cancer [24]. More-
over, only a few studies have been performed to link
HIF-1a mRNA expression and tumour-specific para-
meters [32,33]. Specific antibodies allowing HIF-1a
splice variant detection at the protein level are not cur-
rently available. We used a real-time quantitative reverse
transcription PCR assay to measure mRNA expression
levels of 4 alternatively spliced transcripts of HIF-1a in
breast specimens of 53 primary cancers and 29 normal
tissues or benign lesions.
Interestingly, this work shows for the first time higher
expression levels of two HIF-1a splice variants (HIF-
1a
TAG and HIF-1a
736) in OR-negative carcinomas com-
pared to normal/benign tissues. We also investigated the
prognostic value of HIF-1a transcript expression levels
in breast cancer and found a significant relationship
between either clinicopathological characteristics or
patient metastasis-free survival. First, we found that
HIF-1a
TAG mRNAs levels were substantially higher in
high grade and steroid hormone receptor-negative
tumours. The second and most striking observation was
that HIF-1a
TAG mRNA levels were indicative of shorter
metastasis-free survival, andt h a tt h i sc o r r e l a t e dw i t h
lymph node status. Contrary to the Cayre et al.r e p o r t
[ 2 4 ] ,w ed i dn o tf i n ds i g n i f i c a n tc o r r e l a t i o nb e t w e e n
total HIF-1a mRNA expression and lymph node status
but we observed significant association with tumour
grade. This could be because our series was smaller
than series of Cayre et al. or because the technology
used in our study was more sensitive. In our series, total
HIF-1a mRNA expression negatively correlated with OR
status. Similar to Cayre et al. we did not find any corre-
lation between total HIF-1a mRNA expression and out-
come. Our results showing that HIF-1a
736 mRNA
expression does not correlate with clinicopathological
characteristics of tumours also concur with earlier find-
ings of the same group [24]. In this study, effect of adju-
vant (none, chemotherapy or hormone) treatment on
survival and interactions with expression levels of HIF-
1a splice variants were not checked because of the lim-
ited number of patients in each subgroup. Further
experiments in a larger series are required to answer
this question.
Alternative splicing is known to play an important role
in gene expression regulation by modulating the func-
tional properties of transcription factors [34]. In this
Table 3 Relationship between the hypoxia inducible factor 1a (HIF-1a) splice variant’s expression levels (normalised
copy numbers) and clinicopathological factors or microvessel density in tumour tissue specimens from 53 breast
cancer patients
Variable N Total HIF-1a,
mean (SD)
P value HIF-1a
TAG,
mean (SD)
P value HIF-1a
736,
mean (SD)
P value
Lymph node status:
Negative 25 10.0 (9.0) NS 10.9 (10.9) 0.037 0.19 (0.29) NS
Positive 22 12.8 (7.8) 21.1 (19.2) 0.26 (0.28)
Pathological tumour size:
< 20 mm 28 10.2 (8.3) NS 12.4 (13.2) NS 0.17 (0.26) NS
≥ 20 mm 25 11.8 (8.3) 17.9 (17.4) 0.25 (0.28)
Tumour grade:
1/2 vs 35 9.2 (7.7) 0.048 11.8 (12.3) 0.048 0.19 (0.30) NS
3 17 14.6 (8.7) 21.5 (19.4) 0.23 (0.20)
Peritumoural vascular invasion:
Absent 12 8 (9) 0.028 9.6 (10.1) NS 0.19 (0.36) NS
Present 40 11.9 (8.1) 16.6 (16.6) 0.20 (0.24)
OR status:
Negative 16 14.2 (7.3) 0.024 20.8 (11.9) 0.005 0.25 (0.19) 0.06
Positive 32 10 (8.8) 12.7 (17.1) 0.20 (0.31)
PgR status:
Negative 24 11.8 (7.3) NS 20.08 (17.8) 0.033 0.23 (0.19) 0.077
Positive 26 10.8 (9.4) 11.3 (12.3) 0.2 (0.34)
Tumour microvessel density (low vs high) NS NS NS
Because of missing data, the numbers do not always add up to 53. Expression levels of HIF-1a
516 and HIF-1a
557 mRNA were not included in statistical analyses
because of their very low levels (mean normalised copy numbers < 0.1).
NS = non-significant; OR = oestrogen receptor; PgR = progesterone receptor.
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properties of transcription factors [35], introduce or
eliminate activating domains or increase the in vivo sta-
bility of a given isoform [36]. Moreover, the abundance
of specific isoforms is likely to result from differential
expression, RNA stability and selective splicing process
leading to an increase of some mRNA species. Recent
evidence indicates that in several cancers the ratio of
splice variants is dramatically altered and that differen-
tial expression of alternatively spliced isoforms in cancer
patients can have severe implications for clinical out-
come [37]. Remarkably, statistical association has pre-
viously been reported between HIF-1b splicing variant
expression, oestrogen receptors and breast cancer survi-
val [38]. It should be noted that the primers designed
on exons 1 and 2 in our study allowed quantification of
the HIF-1a
TAG sequence present in both HIF-1a
827 and
HIF-1a
736 splice variants [17]. The HIF-1a
TAG transcript
is characterised by insertiono fat h r e eb a s ep a i r sT A G
insertion that may be generated by the use of two
potential splice acceptor dinucleotides (AG) of intron 1
at a splice junction site as previously described [39,1].
This splicing results in the replacement of Lys
12 by
Asn
12 and the addition of Arg
13 residue located
upstream from the bHLH domain of the protein. This
replacement may modify the DNA binding affinity of
the protein complex as previously shown for Arg
14 and
Arg
15 residues in aryl hydrocarbon receptor (AHR)/aryl
hydrocarbon receptor nuclear translocator (ARNT) het-
erodimer [40]. Further biochemical and structural stu-
dies are required for a better understanding of the
functional properties of this variant.
Conclusions
To our knowledge, our results suggest for the first time
that at least one HIF-1a splice a variant may be a mar-
ker for the advanced clinical and oestrogen-resistant
Table 4 Univariate and multivariate (backward conditional selection) Cox regression analysis of metastasis-free
survival (MFS) in breast cancer patients considering clinicopathological characteristics, tumour microvessel density
and hypoxia inducible factor 1a (HIF-1a)
TAG mRNA levels
Characteristics Univariate analysis of MFS,
Exp B (95% CI)
P value Multivariate analysis of MFS,
Exp B (95% CI)
P value
Age, years:
< 50 1 0.561
≥ 50 1.32 (0.52 to 3.37)
Positive lymph node:
0 1 0.003 1 0.005
1 to 3 8.00 (2.56 to 24.81) 5.56 (1.75 to 17.63)
4 to 9 7.50 (1.70 to 30.00) 6.68 (1.48 to 30.14)
> 10 1.20 (0.14 to 10.00) 0.48 (0.05 to 4.25)
Pathological tumour size, mm:
< 10 1 0.39
10 to 20 1.10 (0.10 to 8.70)
21 to 49 2.40 (0.30 to 18.90)
> 50 2.70 (0.20 to 42.90)
Tumour grade:
1/2 vs 1 0.24
3 1.70 (0.70 to 4.40)
Peritumoural vascular invasion:
Absent 1 0.104
Present 3.40 (0.80 to 14.80)
OR status:
Positive
Negative 0.33 (0.13 to 0.85) 0.021
PgR status:
Positive
Negative 0.20 (0.07 to 0.60) 0.005 0.23 (0.07 to 0.72) 0.012
Tumour microvessel density 1.02 (0.07 to 0.60) 0.22
HIF-1a
TAG mRNA levels 1.03 (1.00 to 1.05) 0.01
OR = oestrogen receptor; PgR = progesterone receptor, Exp B = exponential of beta
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Page 9 of 11stage of breast cancer. Based on their correlation with
survival, HIF-1a
TAG mRNA levels may be a potential
useful prognostic indicator whose value should be
further validated in prospective studies.
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